Loading news...
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026
Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,325 shares of the company's stock after buying an additional 13,617 shares during the period. Bridgefront Capital
Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 313,078 shares of the company's stock after selling 116,206 shares during the period. Citigroup Inc. owned approximately 0.24% of Vaxcyte worth $11,277,000 as
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027 Company Advancing Early-Stage Pipeline, Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Group A Strep, in 2026 Company Advances Global and U.S. Manufacturing Capabilities to Support Commercialization of Pneumococcal Conjugate Vaccines with Completion of Dedicated Lonza Facility and Initiation of North Carolina Fill-Finish Line Buildout Approximately $2.4 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 ; Excludes Approximately $600.2 Million in Net Proceeds from February 2026 Equity Offering Company to Host Webcast/Conference Call Today at 4:30 p.m. ET / 1:30 p.m.
China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,756 shares of the company's stock after selling 9,154 shares during
Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company's pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal conjugate vaccines and broader coverage Chief Executive Officer Grant Pickering said Vaxcyte has
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Federated Hermes Inc. raised its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 6,856.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,156 shares of the company's stock after acquiring an additional 17,895 shares during the quarter.
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants.
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026
SG Americas Securities LLC increased its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 129.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,558 shares of the company's stock after acquiring an additional 14,421 shares during the period. SG
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued
The CTO sold 9,743 shares. The sale represented 28.9% of Dhaliwal's holdings.
Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) insider Harpreet Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the sale, the insider directly owned 23,928 shares in the company, valued at approximately $1,117,198.32.